Lipigon Pharmaceuticals AB engages in the development of drugs for diseases caused by disruptions in the body's handling of lipids. It focuses on small molecules, gene therapy, and antisense for patients with lipid disorders and other cardiometabolic risk factors. The company was founded by Stefan Kristoffer Nilsson on April 6, 2010 and is headquartered in Umeå, Sweden.